Not all companies out there are worth investing in and Sahm Adrangi is one of the top investors in the country today that is doing his duty to inform other investors and the general public of companies that are an issue. The latest company that has taken fire from Kerrisdale Capital, Sahm Adrangi’s investment company, is Proteostasis. This biotech firm has made claims recently that they have had great success developing a new drug for cystic fibrosis patients. So far, Proteostasis claims this drug will dramatically increase lung performance for patients.
In order to get to the bottom of whether or not these claims are good, Sahm Adrangi and Kerrisdale has done some digging into the biotech firm. Unfortunately, what Sahm has found is not so good for those who might be excited about this new drug. CFTR amplifier PTI-428 is what Proteostasis is calling their product, which Sahm is calling a drug cocktail. According to the report, Proteostasis only had four subjects for their testing, which means this was a very small scale test that cannot be accurately assessed based on the presented data. Not only is the data incomplete, but the results are messy and practically missing, which causes Sahm Adrangi to believe these statements are likely false or due to very poor testing procedures by the biotech company. The placebo test conducted found a drop in lung performance as well, meaning their statements that this drug can increase lung performance cannot be true.
Due to all of these concerns, Kerrisdale has taken the short position with Proteostasis. This means they will continue to profit as the stock value of Proteostasis drops, which it has already started doing since Kerrisdale’s negative report went public. This is mostly because of other investors that are keen to follow the advice of Sahm Adrangi, who happens to be a high-profile investor in the U.S. that regularly states his opinions on companies and calls them out for their shady practices. Sahm has an impressive track record of success, couple that with hardly being wrong in his investments or arguments, most investors have started following in his footsteps.